Drugs / amsacrine

Trials 5

198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 34 trials
Phase 3 NCT00003436 Jul 1998 → Dec 2005 leukemia, myelodysplastic syndrome Medical Research Council Completed No outcome recorded
Phase 3 NCT00002719 Dec 1995 → Nov 2001 leukemia, neutropenia European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 3 NCT00002658 Jan 1994 → ? leukemia, neutropenia Medical Research Council Unknown No outcome recorded
Phase 3 NCT01324063 Nov 1986 → Jun 1994 myeloid leukemia European Organisation for Research and Treatment of Cancer - EORTC Completed No outcome recorded
Phase 41 trial · 1 missed
Phase 4 NCT00180102 Dec 2003 → Nov 2009 acute myeloid leukemia Technical University Dresden Completed Missed primary
Comparator or background therapy5 trials
Phase 1/2 NCT05807932 Background Jun 2023 → Apr 2029 expected acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome Heinrich-Heine University, Duesseldorf Recruiting No outcome recorded
Phase 1/2 NCT00840684 Background Jan 2009 → May 2011 leukemia Institut Paoli-Calmettes Completed No outcome recorded
Phase 2 NCT01423175 Comparator Jul 2011 → Jan 2015 acute myeloid leukemia, myelodysplastic syndrome Hannover Medical School Unknown No outcome recorded
Phase 2/3 NCT01228331 Comparator Oct 2010 → Dec 2019 leukemia University Medical Center Hamburg-Eppendorf Completed No outcome recorded
Phase 3 NCT03765541 Background Jan 2020 → May 2024 acute myeloid leukemia University Hospital, Toulouse Terminated No outcome recorded Stop: Enrollment

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as amsacrine “FLAMSA (consisting of one dose of fudarabine, amsacrine and ara-C for four days)” NCT01423175 ↗
9

NCT00002658 ↗

NCT00003436 ↗

NCT00840684 ↗

NCT00002719 ↗

NCT05807932 ↗

NCT03765541 ↗

NCT00180102 ↗

NCT01324063 ↗

NCT01228331 ↗

Known as Acridinylanisidide ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Amekrin ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Amsacrina ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as AMSACRINE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Amsidil ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Amsidine ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Amsidyl ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as CI-880 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as Lamasine ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as M-AMSA ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as NCI-249992 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as NSC-156303 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as NSC-249992 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as SN-11841 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Known as SN-21429 ChEMBL registry synonym — accepted as the source's own label CHEMBL43 ↗
Modality Small molecule — CHEMBL43 ↗
Route Intravenous “amsacrine IV over 1 hour” NCT00002658 ↗